JP2023508052A5 - - Google Patents

Info

Publication number
JP2023508052A5
JP2023508052A5 JP2022538810A JP2022538810A JP2023508052A5 JP 2023508052 A5 JP2023508052 A5 JP 2023508052A5 JP 2022538810 A JP2022538810 A JP 2022538810A JP 2022538810 A JP2022538810 A JP 2022538810A JP 2023508052 A5 JP2023508052 A5 JP 2023508052A5
Authority
JP
Japan
Prior art keywords
methyl
oxo
naphthyridine
carbonitrile
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022538810A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023508052A (ja
JP7653440B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/066507 external-priority patent/WO2021133750A1/en
Publication of JP2023508052A publication Critical patent/JP2023508052A/ja
Publication of JP2023508052A5 publication Critical patent/JP2023508052A5/ja
Application granted granted Critical
Publication of JP7653440B2 publication Critical patent/JP7653440B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022538810A 2019-12-23 2020-12-22 T細胞アクティベーターとして有用な置換二環化合物 Active JP7653440B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201911053552 2019-12-23
IN201911053552 2019-12-23
PCT/US2020/066507 WO2021133750A1 (en) 2019-12-23 2020-12-22 Substituted bicyclic piperidine derivatives useful as t cell activators

Publications (3)

Publication Number Publication Date
JP2023508052A JP2023508052A (ja) 2023-02-28
JP2023508052A5 true JP2023508052A5 (https=) 2023-12-07
JP7653440B2 JP7653440B2 (ja) 2025-03-28

Family

ID=74191945

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538810A Active JP7653440B2 (ja) 2019-12-23 2020-12-22 T細胞アクティベーターとして有用な置換二環化合物

Country Status (27)

Country Link
US (1) US11964973B2 (https=)
EP (1) EP4081523B1 (https=)
JP (1) JP7653440B2 (https=)
KR (1) KR20220119455A (https=)
CN (1) CN114901660B (https=)
AR (1) AR120823A1 (https=)
AU (1) AU2020412615A1 (https=)
BR (1) BR112022012195A2 (https=)
CA (1) CA3163013A1 (https=)
CL (1) CL2022001710A1 (https=)
CO (1) CO2022008675A2 (https=)
DK (1) DK4081523T3 (https=)
ES (1) ES3008848T3 (https=)
FI (1) FI4081523T3 (https=)
HR (1) HRP20250149T1 (https=)
HU (1) HUE070934T2 (https=)
IL (1) IL294272A (https=)
LT (1) LT4081523T (https=)
MX (1) MX2022007842A (https=)
PE (1) PE20221487A1 (https=)
PL (1) PL4081523T3 (https=)
PT (1) PT4081523T (https=)
RS (1) RS66482B1 (https=)
SI (1) SI4081523T1 (https=)
SM (1) SMT202500102T1 (https=)
TW (1) TWI843922B (https=)
WO (1) WO2021133750A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL294032A (en) 2019-12-24 2022-08-01 Carna Biosciences Inc Compounds that regulate diacylglycerol kinase
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
WO2023122778A1 (en) * 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
WO2023150186A1 (en) * 2022-02-01 2023-08-10 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
EP4486741A4 (en) 2022-03-01 2026-04-08 Insilico Medicine Ip Ltd Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses
WO2023165525A1 (en) * 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
US20250215014A1 (en) * 2022-03-31 2025-07-03 InventisBio Co., Ltd. Kinase inhibitors, preparation methods and uses thereof
US12600723B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
US12600722B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
WO2024137865A1 (en) * 2022-12-22 2024-06-27 Gossamer Bio Services, Inc. Compounds useful as t cell activators
EP4658650A1 (en) * 2023-02-02 2025-12-10 Beone Medicines I GmbH Heterocyclic compounds
EP4661869A1 (en) 2023-02-06 2025-12-17 Bayer Aktiengesellschaft Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators
WO2025030002A2 (en) * 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324893A (en) 1979-04-18 1982-04-13 American Home Products Corporation 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
BR0312204A (pt) 2002-06-27 2005-04-26 Schering Ag Antagonista de receptor ccr5 de quinolina substituìda
GB0230018D0 (en) 2002-12-23 2003-01-29 Syngenta Ltd Fungicides
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
TWI289141B (en) 2003-03-11 2007-11-01 Hoffmann La Roche F. Ag. Quinolinone derivatives and uses thereof
WO2004087880A2 (en) 2003-03-26 2004-10-14 Bayer Pharmaceuticals Corporation Compounds and their use to treat diabetes and related disorders
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
EP1660087A2 (en) 2003-07-22 2006-05-31 Janssen Pharmaceutica N.V. Quinolinone derivatives as inhibitors of c-fms kinase
CN1839133A (zh) 2003-08-22 2006-09-27 阿文尼尔药品公司 作为巨噬细胞移动抑制因子的抑制剂的取代的二氮杂萘衍生物及其在治疗人类疾病中的应用
US7381401B2 (en) * 2004-01-08 2008-06-03 The University Of Chicago T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
US8450351B2 (en) 2005-12-20 2013-05-28 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
GB0605689D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic compounds
JP5422204B2 (ja) * 2006-03-30 2014-02-19 国立大学法人 千葉大学 DGKα阻害剤を含有する抗癌剤
JP2007308402A (ja) 2006-05-17 2007-11-29 Sumitomo Chemical Co Ltd シンナモイル化合物及びその用途
JP2007308441A (ja) 2006-05-22 2007-11-29 Sumitomo Chemical Co Ltd 含複素環化合物及びその用途
WO2008036642A2 (en) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
AU2007301958A1 (en) 2006-09-29 2008-04-03 Tibotec Pharmaceuticals Ltd. Quinolinone derivatives
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
WO2009156652A1 (fr) 2008-05-29 2009-12-30 Saint-Gobain Centre De Recherches Et D'etudes Europeen Structure en nid d'abeille a base de titanate d'aluminium
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010042489A2 (en) 2008-10-06 2010-04-15 Emory University Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-gitr 항체
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
EP2542256B1 (en) 2010-03-04 2019-05-22 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトcsf−1rに対する抗体及びその使用
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
WO2012142498A2 (en) * 2011-04-13 2012-10-18 Innovimmune Biotherapeutics, Inc. Mif inhibitors and their uses
NO2694640T3 (https=) 2011-04-15 2018-03-17
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン,エルエルシー B7−h1およびpd−1に結合する抗体およびその他の分子
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-pd-l1 항체 및 그의 용도
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
KR20140127855A (ko) 2012-02-06 2014-11-04 제넨테크, 인크. Csf1r 억제제를 사용하는 조성물 및 방법
AR089939A1 (es) 2012-02-09 2014-10-01 Glenmark Pharmaceuticals Sa COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
RU2670743C9 (ru) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
WO2014039513A2 (en) 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
PT3889145T (pt) 2015-12-17 2024-04-02 Merck Patent Gmbh 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários
US10946020B2 (en) 2016-04-06 2021-03-16 University Of Virginia Patent Foundation Compositions and methods for treating cancer
CN110366550A (zh) 2016-12-22 2019-10-22 美国安进公司 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
AU2018273356B2 (en) 2017-05-22 2021-09-16 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US12187687B2 (en) 2017-06-26 2025-01-07 University Of Virginia Patent Foundation Compositions and uses thereof
AU2018340475B2 (en) 2017-09-28 2023-01-19 Transthera Sciences (Nanjing), Inc. PDE9 inhibitor and use thereof
KR102767739B1 (ko) 2018-06-27 2025-02-12 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물
CN112585139B (zh) 2018-06-27 2023-12-01 百时美施贵宝公司 用作t细胞激活剂的萘啶酮化合物
CN111471059B (zh) * 2019-01-23 2022-12-02 药捷安康(南京)科技股份有限公司 Pde9抑制剂及其用途
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
US20230062100A1 (en) 2019-11-28 2023-03-02 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
US20230064809A1 (en) 2019-11-28 2023-03-02 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
CR20220236A (es) 2019-11-28 2022-10-03 Bayer Pharma AG Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune

Similar Documents

Publication Publication Date Title
JP2023508052A5 (https=)
HRP20250149T1 (hr) Supstituirani biciklični derivati peridina korisni kao aktivatori t stanica
JP6853307B2 (ja) ヘテロアリール化合物およびそれらの使用
KR101671341B1 (ko) 다이아미노피리미딘 유도체 및 그의 제조방법
US9840498B2 (en) Substituted quinazolin-4-one derivatives
RU2529019C2 (ru) Модулирующие jak киназу хиназолиновые производные и способы их применения
KR102835667B1 (ko) Parp14 억제제로서의 퀴나졸리논
JP6709786B2 (ja) Egfrモジュレーターとしての置換2−アミノピリミジン誘導体
JP5656874B2 (ja) Pde9阻害剤として使用されるアミノヘテロ環化合物
KR101467858B1 (ko) mTOR 및 PI3K 억제제로서의 신규 피리미딘 화합물
JP7749602B2 (ja) アミドピリミドン誘導体
JP4917109B2 (ja) キナーゼ阻害剤としてのヘテロ二環式カルボキサミド
JP2008526804A (ja) キナーゼ阻害剤としてのジ置換ウレア
KR20170086547A (ko) 헤테로아릴 화합물 및 이의 용도
RU2016103938A (ru) Модуляторы протеин-тирозинкиназы и способы их применения
AU2015303641A1 (en) 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof
TW202246232A (zh) Tyk2抑制劑及其用途
CA2724426A1 (en) Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
CN105143215B (zh) 布鲁顿氏酪氨酸激酶抑制剂
JP2012513480A (ja) Jak経路の阻害のための組成物および方法
JP2010513393A (ja) H1受容体アンタゴニストとしての4−ベンジル−l(2h)−フタラジノン
US20240059692A1 (en) New indazole derivatives
ES2607635T3 (es) Derivados tiazol como inhibidores de tirosina quinasa de Bruton
CN111315734A (zh) 作为食欲素受体拮抗剂的经取代的2-氮杂双环[3.1.1]庚烷和2-氮杂双环[3.2.1]辛烷衍生物
JP2006241089A (ja) ピロロピリミジン誘導体またはその塩